PH20203A - An occlusion compound of 2-nitroxymethyl-6-chloropyridine with b-cyclodextrin - Google Patents

An occlusion compound of 2-nitroxymethyl-6-chloropyridine with b-cyclodextrin

Info

Publication number
PH20203A
PH20203A PH31326A PH31326A PH20203A PH 20203 A PH20203 A PH 20203A PH 31326 A PH31326 A PH 31326A PH 31326 A PH31326 A PH 31326A PH 20203 A PH20203 A PH 20203A
Authority
PH
Philippines
Prior art keywords
nitroxymethyl
chloropyridine
cyclodextrin
occlusion compound
occlusion
Prior art date
Application number
PH31326A
Other languages
English (en)
Inventor
Yoshio Ueda
Fumio Shimojo
Kiyoshige Yoshida
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of PH20203A publication Critical patent/PH20203A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PH31326A 1983-10-11 1984-10-11 An occlusion compound of 2-nitroxymethyl-6-chloropyridine with b-cyclodextrin PH20203A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58190345A JPS6081166A (ja) 1983-10-11 1983-10-11 2−ニトロオキシメチル−6−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法

Publications (1)

Publication Number Publication Date
PH20203A true PH20203A (en) 1986-10-20

Family

ID=16256648

Family Applications (1)

Application Number Title Priority Date Filing Date
PH31326A PH20203A (en) 1983-10-11 1984-10-11 An occlusion compound of 2-nitroxymethyl-6-chloropyridine with b-cyclodextrin

Country Status (18)

Country Link
US (1) US4575548A (no)
EP (1) EP0141300A3 (no)
JP (1) JPS6081166A (no)
KR (1) KR850003414A (no)
CN (1) CN85102133A (no)
AU (1) AU576521B2 (no)
CA (1) CA1248523A (no)
DK (1) DK461184A (no)
ES (1) ES536654A0 (no)
FI (1) FI843944L (no)
GR (1) GR80531B (no)
HU (1) HU194285B (no)
IL (1) IL73076A (no)
NO (1) NO843773L (no)
OA (1) OA07832A (no)
PH (1) PH20203A (no)
PT (1) PT79320B (no)
ZA (1) ZA847350B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
JPS60202115A (ja) * 1984-03-27 1985-10-12 Ichiro Shibauchi エポキシ樹脂用硬化剤
ZA885069B (en) * 1987-07-24 1989-03-29 Fujisawa Pharmaceutical Co Sustained-release percutaneous preparations
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA1321192C (en) * 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
EP1176792A1 (en) * 2000-07-24 2002-01-30 Alcatel Method and apparatus for providing an all digital loop with power-optimised mode
US20070010466A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US11812951B2 (en) 2008-06-17 2023-11-14 Apollo Endosurgery Us, Inc. Endoscopic needle assembly
US12108939B2 (en) 2008-06-17 2024-10-08 Boston Scientific Scimed, Inc. Endoscopic tissue grasping systems and methods
CA2692211C (en) * 2009-12-14 2011-09-13 Cellresin Technologies, Llc Maturation or ripening inhibitor release from polymer, fiber, film, sheet or packaging
US10182567B2 (en) 2011-03-27 2019-01-22 Cellresin Technologies, Llc Cyclodextrin compositions, articles, and methods
PT2976946T (pt) 2011-03-27 2017-06-26 Cellresin Tech Llc Composições de ciclodextrina, artigos e métodos
US9320288B2 (en) 2012-11-30 2016-04-26 Cellresin Technologies, Llc Controlled release compositions and methods of using
US9421793B2 (en) 2014-06-26 2016-08-23 Cellresin Technologies, Llc Electrostatic printing of cyclodextrin compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2959580A (en) * 1956-10-17 1960-11-08 Univ Minnesota Formation of inclusion compounds
CH445129A (fr) * 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
JPS56123912A (en) * 1980-03-05 1981-09-29 Nitto Electric Ind Co Ltd Drug-containing tape preparation
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS57142962A (en) * 1981-02-28 1982-09-03 Santen Pharmaceut Co Ltd Cyclodextrin clathrate compound of sulfur-containing compound
JPS6054304B2 (ja) * 1981-10-16 1985-11-29 株式会社バコム ジソピラミド包接化合物
US4425336A (en) * 1982-05-24 1984-01-10 Key Pharmaceuticals, Inc. 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes
DK311683A (da) * 1982-07-26 1984-01-27 Fujisawa Pharmaceutical Co Fremgangsmaade til fremstilling af pyridylalkylnitratforbindelser
JPS6025967A (ja) * 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
DE3329517A1 (de) * 1983-08-16 1985-02-28 Hoechst Ag, 6230 Frankfurt Einschlussverbindung von n,n-dimethyl-2-chlor-5-(3-methyl-2-(phenylimino)-4-thiazolin-4-yl)phenylsulfonamid, verfahren zu ihrer herstellung sowie pharmazeutische praeparate
DE3337802A1 (de) * 1983-10-18 1985-04-25 Merck Patent Gmbh, 6100 Darmstadt Pharmazeutische zubereitung

Also Published As

Publication number Publication date
FI843944A0 (fi) 1984-10-08
CA1248523A (en) 1989-01-10
GR80531B (en) 1985-01-09
IL73076A (en) 1988-05-31
IL73076A0 (en) 1984-12-31
KR850003414A (ko) 1985-06-17
AU3339984A (en) 1985-04-18
DK461184D0 (da) 1984-09-26
CN85102133A (zh) 1987-01-17
DK461184A (da) 1985-04-12
FI843944L (fi) 1985-04-12
HUT36832A (en) 1985-10-28
OA07832A (fr) 1986-11-20
PT79320B (en) 1986-09-08
ZA847350B (en) 1985-10-30
US4575548A (en) 1986-03-11
EP0141300A3 (en) 1986-01-29
JPS6245226B2 (no) 1987-09-25
EP0141300A2 (en) 1985-05-15
ES8506758A1 (es) 1985-08-01
AU576521B2 (en) 1988-09-01
JPS6081166A (ja) 1985-05-09
PT79320A (en) 1984-11-01
HU194285B (en) 1988-01-28
NO843773L (no) 1985-04-12
ES536654A0 (es) 1985-08-01

Similar Documents

Publication Publication Date Title
PH20203A (en) An occlusion compound of 2-nitroxymethyl-6-chloropyridine with b-cyclodextrin
DE3462252D1 (en) Compound
AU586128B2 (en) Catheter
GB8419684D0 (en) Inclusion compound of eicosapentaenoic acid
GB8327926D0 (en) Monoazo compound
AU2951384A (en) Mounting of locks
GB8423460D0 (en) Prostaglandin derivatives
AU557762B2 (en) Hydraulic-elastomeric mount
GB2138335B (en) An assembly of two parts
AU3362784A (en) Fatty ethenord acylammoorganosilicon compound
EP0142943A3 (en) Hydraulic-elastomeric mount
AU3622284A (en) Catheter
GB8313035D0 (en) Compound
AU564260B2 (en) Solutions of 1-naphthylmethylcarbamate
GB8432631D0 (en) Reel assembly
AU567727B2 (en) Preparation of aminonitriles
AU551096B2 (en) Mounting
GB2148291B (en) Prostaglandin derivatives
AU3626384A (en) Herbicidal-composition of s-benzyldipropylthiocarbamate
KR840000864Y1 (en) Connector of the dog-kead
AU567780B2 (en) Chlorocefadroxil monohydrate
GB8302967D0 (en) Morpholinol compound
GB8306449D0 (en) Morpholinol compound
GB8324850D0 (en) Quinolizinone compound
GB8334554D0 (en) Cephalosporin compound